EX-10.1
from 10-Q
9 pages
Fourth Amendment to Oncosignature Companion Diagnostic Agreement This Fourth Amendment to Oncosignature Companion Diagnostic Agreement (This “Fourth Amendment”) Is Effective as of September 30, 2024 (The “Fourth Amendment Effective Date”) by and Between: Acrivon Therapeutics, Inc., a Delaware Corporation With Its Principal Place of Business at 480 Arsenal Way, Suite 100, Watertown, Ma 02472 (“Acrivon”), and Akoya Biosciences, Inc., a Delaware Corporation With Its Principal Place of Business at 100 Campus Drive, 6th Floor, Marlborough, Ma 01752 (“Akoya”). Acrivon and Akoya Are Each Referred to Individually as a “Party” and Together as the “Parties.”
12/34/56
EX-10.4
from 8-K
21 pages
April [__], 2024 [__] Re: Affiliate Registration Rights Agreement Ladies and Gentlemen: Subject to and in Consideration of an Investment in Acrivon Therapeutics, Inc., a Delaware Corporation (The “Company”), by [__] (Collectively, the “Investor”), the Parties to This Letter Hereby Agree as Follows: 1
12/34/56
EX-10.3
from 8-K
7 pages
[__] Re: Publicity and Board Observer Rights Ladies and Gentlemen: Subject to and in Consideration of an Investment in Acrivon Therapeutics, Inc., a Delaware Corporation (The “Company”), by [__] and/or One or More of Its Affiliates (As Defined Below) (Each, an “Investor” and Together, the “Investors”), the Parties to This Letter Hereby Agree as Follows: 1
12/34/56
EX-10.16
from 10-K
5 pages
Certain Confidential Information, Marked by [***], Has Been Excluded From This Exhibit Because It (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Third Amendment to Oncosignature Companion Diagnostic Agreement This Third Amendment to Oncosignature Companion Diagnostic Agreement (The “Third Amendment”) Is Made and Entered Into as of December 4, 2023 (The “Third Amendment Effective Date”) by and Between: Acrivon Therapeutics, Inc., a Delaware Corporation With Its Principal Place of Business at 480 Arsenal Way, Suite 100, Watertown, Ma 02472 (“Acrivon”), and Akoya Biosciences, Inc., a Delaware Corporation With Its Principal Place of Business at 100 Campus Drive, 6th Floor, Marlborough, Ma 01752 (“Akoya”). Acrivon and Akoya Are Each Referred to Individually as a “Party” and Together as the “Parties.”
12/34/56
EX-10.2
from 10-Q
4 pages
Second Amendment to Oncosignature Companion Diagnostic Agreement This Second Amendment to Oncosignature Companion Diagnostic Agreement (The “Second Amendment”) Is Made and Entered Into as of June 19, 2023 (The “Second Amendment Effective Date”) by and Between: Now Therefore, in Consideration of the Mutual Promises and Agreement Set Forth Herein, and for Other Good and Valuable Considerations, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Parties Agree as Follows: 1
12/34/56
EX-10.2
from 8-K
9 pages
Employment Contract on This Day This the Following Contract of Employment (“The Agreement”) Has Been Entered Into Between (1) Acrivon Ab, Org. Nr. 559152-0944, and (2) Kristina Masson, 19800313-0161, Nordanväg 8, 222 28 Lund, Sweden. Acrivon Ab Hereinafter Referred to as (”Employer”). Kristina Masson, Hereinafter Referred to as (“Employee”). the Employer and the Employee Are Collectively Referred to as (“The Parties”) and Separately as (“Party”)
12/34/56
